Community stack
Wolverine Stack
BPC-157 + TB-500
Community and vendor sources frame the Wolverine Stack as an injury-recovery combination aimed at tendon, ligament, joint, muscle and general soft-tissue repair - named for the comic-book character known for rapid healing. It is essentially the two most-discussed 'healing' peptides bundled together for a broader recovery effect than either alone.
Community stack - not clinically tested
No clinical trial has tested this exact combination. The rationale below is built from each compound's individual research, and the dosing is community-derived. None of these compounds is FDA-approved for this use.
What is in it
Why people run it
The pairing rests on a local-plus-systemic logic repeated across both sources fetched: BPC-157 is positioned as the local repair signal, acting at the injury site to drive angiogenesis (new blood vessel formation) and growth-factor signaling, while TB-500 is positioned as the systemic signal - an actin-binding peptide that promotes cell migration and helps mobilize repair cells to injured tissue throughout the body. Peptide Advisors describes BPC-157 as promoting 'blood vessel formation and growth factors' and TB-500 as binding actin 'to enable cell migration,' explicitly calling them different healing stages rather than the same mechanism twice. This logic traces to each compound's individually studied preclinical actions (BPC-157's angiogenic effects, and cell migration tied to the parent molecule of TB-500, thymosin beta-4), not to any study of the two peptides given together.
Community dosing
communityTwo formats show up in vendor guides: a pre-blended vial (the cited example runs 1 mg of each peptide per dose), or separate vials with BPC-157 dosed daily (250-500 mcg) alongside TB-500 loaded at 2-5 mg twice weekly before dropping to a lower maintenance frequency. Cycles commonly run 6-12 weeks. Peptide Dosing Protocols cites a 20 mg combined-blend vial reconstituted with 2 mL bacteriostatic water as a common concentration (10 mg/mL total).
Work out your draw in the calculatorThe honest caveat
This is a community-and-vendor stack name, not a clinical protocol. No clinical trial has tested BPC-157 and TB-500 together - Peptide Dosing Protocols states outright that 'No published clinical trial has tested BPC-157 + TB-500 together,' and Peptide Advisors confirms 'No peer-reviewed clinical trial has tested BPC-157 and TB-500 together in humans,' adding that claims about the stack are extrapolated from separate animal studies of each compound. Neither peptide is FDA-approved for any use, and both appear on WADA's prohibited list.
Sources
- [1]Wolverine Stack Protocol: BPC-157 + TB-500States 'No published clinical trial has tested BPC-157 + TB-500 together'; describes pre-blended (1 mg/day) and separate-vial (BPC-157 250-500 mcg/day, TB-500 2-5 mg twice weekly) community dosing over 6-12 week cycles, and a 20 mg blend + 2 mL bacteriostatic water reconstitution.
- [2]Wolverine Stack Guide: BPC-157 + TB-500 Peptide Protocol, Dosage and Recovery ResultsDescribes the mechanistic rationale (BPC-157 as local repair signal via angiogenesis/growth factors, TB-500 as systemic cell-migration signal via actin binding); states 'No peer-reviewed clinical trial has tested BPC-157 and TB-500 together in humans' and that claims are extrapolated from individual-compound animal research.
Other stacks